logo
  

Arch Coal Suspends FY20 Sales Volume Guidance, Dividend - Quick Facts

While reporting financial results for the first quarter on Thursday, coal producer Arch Coal, Inc. (ARCH) said it is suspending its total sales volume outlook for the full year 2020, given the current market uncertainty amid the coronavirus (COVID-19) outbreak.

However, Arch Coal is now forecasting a reduction in 2020 capital spending of $20 million, the majority of which is related to its thermal operations.

Its board also elected to suspend the quarterly dividend in order to preserve Arch's financial flexibility in light of the ongoing uncertainty around the coronavirus pandemic.

"While the board views this step as judicious in the current macroeconomic environment, we currently expect the suspension of the dividend to be temporary," said Matthew Giljum, Arch's CFO.

During the quarter, Arch conducted a voluntary separation program in an effort to better align its corporate support structure with its current operating profile and long-term strategic direction. Initiated in late February, the program will result in a 30-percent reduction in corporate staffing levels, and should translate into annual cost savings of approximately $6 million in 2020 and between $12 million and $15 million in 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT